Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration

S S Boiko; R U Ostrovskaya; V P Zherdev; S A Korotkov; T A Gudasheva; T A Voronina; S B Seredenin

doi:10.1007/BF02439270

Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration

Bull Exp Biol Med. 2000 Apr;129(4):359-61. doi: 10.1007/BF02439270.

Authors

S S Boiko¹, R U Ostrovskaya, V P Zherdev, S A Korotkov, T A Gudasheva, T A Voronina, S B Seredenin

Affiliation

¹ Laboratory of Pharmacokinetics, Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow.

PMID: 10977920
DOI: 10.1007/BF02439270

Abstract

Pharmacokinetics of GVS-111, a new acylprolyldipeptide with nootropic properties and its penetration across the blood-brain barrier were studied in rats using HPLC. It was found that the dipeptide is absorbed in the gastrointestinal tract, enters the circulation, and penetrates through the blood-brain barrier in an unmodified state.

MeSH terms

Administration, Oral
Animals
Blood-Brain Barrier / drug effects*
Dipeptides / administration & dosage
Dipeptides / pharmacokinetics*
Male
Nootropic Agents / administration & dosage
Nootropic Agents / pharmacokinetics*
Rats

Substances

Dipeptides
Nootropic Agents
ethyl phenylacetyl-Pro-Gly